Herantis Pharma Plc announced that the Company has nominated HER-096 as the preclinical xCDNF candidate to take forward into further preclinical development for the treatment of Parkinson's Disease (PD) and other neurodegenerative diseases. HER-096 was selected based on clear and compelling preclinical data including that it: Effectively penetrates the Blood-Brain-Barrier (BBB) - Potently protects neurons and restores their functional phenotype - Significantly reduces aggregation of the toxic protein alpha-synuclein and the associated neuroinflammation - Restores proteostasis. As a result the Herantis pipeline now comprises two promising Parkinsons assets: CDNF (Cerebral Dopamine Neurotrophic Factor), a clinical stage biological, and HER-096 a preclinical stage compound. The two assets will continue to be developed as separate projects in tandem.